 A blockbuster deal announced earlier this week could be a sign of a bright future for cannabidiol-oriented pharmaceutical companies. On Wednesday, cancer therapy developer Jazz Pharmaceuticals PLC NASDAQ:JAZZ struck a US7.2 billion agreement with UK-based GW Pharmaceuticals PLC NASDAQ:GWPH, makers of childhood epilepsy treatment Epidiolex, the first cannabis-based medicine approved in the US. 